Document Detail


Twist form of teleocidin derivatives is active in in vivo tumor promotion by (-)-benzolactam-V8-310.
MedLine Citation:
PMID:  9635501     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Teleocidin derivatives and the core structure, (-)-indolactam-V ((-)-IL-V), adopt two conformations in solution, the "twist" and the "sofa" forms. (-)-Benzolactam-V8-310 ((-)-BL-V8-310), which specifically adopts the twist form in solution, has been reported to have a significant effect on HL-60 cells and protein kinase C affinity. In this paper, we describe the biological activity with regard to tumor promotion on mouse skin and the wide variety of biological activity of (-)-BL-V8-310 and its derivatives. In both twist and sofa forms (-)-BL-V8-310 inhibited specific 3H-12-O-tetradecanoylphorbol-13-acetate (TPA) binding to a particulate fraction of mouse skin more strongly than (-)-IL-V. The doses for 50% inhibition (IC50) of (-)-IL-V, (-)-BL-V8-310, and teleocidin B-4 were 1000, 400 and 12 nM, respectively. As for the induction of tumor necrosis factor-alpha (TNF-alpha) release into the medium from HL-60 cells, the EC200 values, which are the concentrations of the compound required to achieve 200 pg/ml TNF-alpha in the medium, were 1700, 500 and 19 nM for (-)-IL-V, (-)-BL-V8-310 and teleocidin B-4, respectively. The same amounts (5.5 nmol per application) of (-)-BL-V8-310 and teleocidin B-4, induced tumors on mouse skin initiated with 7,12-dimethylbenz(a)anthracene (DMBA) in 13.3% and 86.7% of tumor-bearing mice, respectively, in week 20. These results confirmed that the twist form of teleocidin derivatives is the active form as far as the induction of biological activity is concerned. Also (-)-BL-V8-310 is a new synthetic tumor promoter designed from data obtained using the receptor cavity model of TPA-type tumor promoters.
Authors:
S Okabe; N Sueoka; A Komori; M Suganuma; Y Endo; K Shudo; H Fujiki
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Biological & pharmaceutical bulletin     Volume:  21     ISSN:  0918-6158     ISO Abbreviation:  Biol. Pharm. Bull.     Publication Date:  1998 May 
Date Detail:
Created Date:  1998-08-24     Completed Date:  1998-08-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9311984     Medline TA:  Biol Pharm Bull     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  465-8     Citation Subset:  IM    
Affiliation:
Saitama Cancer Center Research Institute, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Carcinogens / chemistry,  metabolism,  pharmacology*
Female
HL-60 Cells
Humans
Lactams / chemistry,  metabolism,  pharmacology*
Lyngbya Toxins / chemistry,  pharmacology*
Mice
Molecular Conformation
Skin / drug effects,  metabolism
Tetradecanoylphorbol Acetate / metabolism
Tumor Necrosis Factor-alpha / metabolism
Chemical
Reg. No./Substance:
0/Carcinogens; 0/Lactams; 0/Lyngbya Toxins; 0/Tumor Necrosis Factor-alpha; 0/benzolactam V8-310; 16561-29-8/Tetradecanoylphorbol Acetate; 78474-55-2/teleocidin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Histamine-releasing properties of T-3762, a novel fluoroquinolone antimicrobial agent in intravenous...
Next Document:  Antihypertensive effect of sesamin. III. Protection against development and maintenance of hypertens...